Douglas Onsi

Director, President, Chief Executive Officer, Chief Financial Officer, Treasurer & Secretary at Leap Therapeutics, Inc.

Douglas Onsi

Douglas Onsi

Director, President, Chief Executive Officer, Chief Financial Officer, Treasurer & Secretary at Leap Therapeutics, Inc.

Overview
Career Highlights

Tolerx, Inc.
TetraLogic Research & Development Corp.
Leap Therapeutics, Inc.

RelSci Relationships

1536

Number of Boards

17

Birthday

1969

Age

52

Relationships
RelSci Relationships are individuals Douglas Onsi likely has professional access to. A relationship does not necessarily indicate a personal connection.

Managing Director at HealthCare Ventures LLC

Relationship likelihood: Strong

Managing Director at HealthCare Ventures LLC

Relationship likelihood: Strong

Co-Founder at HealthCare Ventures LLC

Relationship likelihood: Strong

President at HealthCare Ventures LLC

Relationship likelihood: Strong

Managing Director & General Partner at HealthCare Ventures LLC

Relationship likelihood: Strong

Co-Founder at Potentia Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Manufacturing Officer at Leap Therapeutics, Inc.

Relationship likelihood: Strong

President at Novartis Institutes for BioMedical Research, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Adheron Therapeutics, Inc.

Relationship likelihood: Strong

Partner at Morgan, Lewis & Bockius LLP

Relationship likelihood: Strong

Paths to Douglas Onsi
Potential Connections via
Relationship Science
You
Douglas Onsi
Director, President, Chief Executive Officer, Chief Financial Officer, Treasurer & Secretary at Leap Therapeutics, Inc.
Education
JD Degree
Class of 1993

The University of Michigan, founded in 1817, celebrates a long and distinguished history. It was in 1787 that the Northwest Territorial Ordinance provided public land for this and other Midwestern universities and established a tradition of respect for excellence in higher education. Three Native American nations—the Ojibwa (Chippewa), Odawa (Ottawa), and Bodewadini (Potawatomi)—subsequently granted certain lands for use of the University of Michigan and by the end of the 19th century, Michigan was the largest and most generously supported public university in America and already a leader in graduate education. The University of Michigan Law School, one of the oldest law schools in the nation, was founded in 1859. But unlike other highly selective law schools established in that era, admission was never restricted to the privileged. When Gabriel Hargo graduated from the Law School in 1870, Michigan—then the largest law school in the country—became the second American university to confer a law degree on an African American. That same year, Michigan was the first major law school to admit a woman, and in 1871, graduate Sarah Killgore became the first woman with a law degree in the nation to be admitted to the bar; by 1890, Michigan had graduated more women than any other law school. That commitment to access and diversity joined an equally powerful commitment to excellence, which continues to this day.

B.S. Degree in Biology
Class of 1990

Cornell is a privately endowed research university and a partner of the State University of New York. As the federal land-grant institution in New York State, they have a responsibility—unique within the Ivy League—to make contributions in all fields of knowledge in a manner that prioritizes public engagement to help improve the quality of life in our state, the nation, the world.

Career History
Venture Partner
2010 - Current

Healthcare Ventures invests in pre-clinical or early clinical stage focused companies located in the US. The firm targets companies operating in the fields of life sciences, pharmaceutical and biotechnology sector. It provides financing for early and later stage capital requirements with an investment size up to $20 million.

President, Secretary, Treasurer & Director
Current

TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA.

Portfolio Manager, Oncology
2004 - 2007

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Boards & Committees
Member, Board of Directors
2011 - Current

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Director
2011 - Current

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

Director
2010 - Current
President, Secretary, Treasurer & Director
Current

TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA.

Council Member
Prior

Cornell is a privately endowed research university and a partner of the State University of New York. As the federal land-grant institution in New York State, they have a responsibility—unique within the Ivy League—to make contributions in all fields of knowledge in a manner that prioritizes public engagement to help improve the quality of life in our state, the nation, the world.

Political Donations
$500
2008

Former Senator from Massachusetts

$250
2004

Former Senator from Massachusetts

Transactions
Details Hidden

Leap Therapeutics, Inc. issued . USD Common Stock and Warrants

Details Hidden

Leap Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Leap Therapeutics, Inc. raised money in a private placement transaction

Investments
Details Hidden

Togga, Inc. operates fantasy soccer platform for the English premier league. The company was founded by Scott Faust and is headquartered in Austin, TX.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Douglas Onsi. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Douglas Onsi's profile does not indicate a business or promotional relationship of any kind between RelSci and Douglas Onsi.